Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
Rhea-AI Summary
Xilio Therapeutics (Nasdaq: XLO), a clinical-stage biotechnology company focused on developing tumor-activated immuno-oncology therapies, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The company's president and CEO, René Russo, Pharm.D., will engage in a fireside chat on September 4, 2024, at 7:00 am EDT.
Investors and interested parties can access a live webcast of the presentation through the 'Events & Presentations' section of Xilio's website. The webcast will remain available for 30 days following the event, providing an opportunity for those unable to attend live to catch up on the company's latest developments and strategies in the field of cancer treatment.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, XLO declined 0.79%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
WALTHAM, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm.D., president and chief executive officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024, at 7:00 am EDT.
A live webcast can be accessed under “Events & Presentations” in the Investors & Media section of the Xilio Therapeutics website at https://ir.xiliotx.com/. A replay of the webcast will be archived on the website for 30 days following the presentation.
About Xilio Therapeutics
Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers). Learn more by visiting www.xiliotx.com and follow us on LinkedIn (Xilio Therapeutics, Inc.).
Investor and Media Contact:
Scott Young
Vice President, Investor Relations and Corporate Communications
investors@xiliotx.com
FAQ
When is Xilio Therapeutics (XLO) presenting at the Morgan Stanley Healthcare Conference?
Who will be representing Xilio Therapeutics (XLO) at the Morgan Stanley conference?
How can I watch Xilio Therapeutics' (XLO) presentation at the Morgan Stanley conference?
How long will the replay of Xilio Therapeutics' (XLO) Morgan Stanley conference presentation be available?
What is the focus of Xilio Therapeutics' (XLO) research and development?
